Last reviewed · How we verify
FMT-c
At a glance
| Generic name | FMT-c |
|---|---|
| Sponsor | Universidad Autonoma de Nuevo Leon |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Intestinal Microbiota Transplantation in Patients With Chronic Heart Failure (PHASE1)
- Healthy-donor Microbiome MTP-101-C in Steroid Relapse/Refractory Immune-related Cutaneous Adverse Events (irCAEs) and Immune-mediated Colitis (IMC) (PHASE2)
- Feasibility Study of MET-4: Evaluating Fecal Microbiome Effects in Immunotherapy Patients (PHASE2, PHASE3)
- Fecal Microbiota Transplantation in Children With ASD (NA)
- A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection (PHASE3)
- ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI (PHASE2)
- Safety and Efficacy of Capsule FMT in Treatment-naïve Patients With Newly Diagnosed Chronic Inflammatory Diseases (PHASE2)
- Stool Transplant to Control Treatment-related Diarrhea (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FMT-c CI brief — competitive landscape report
- FMT-c updates RSS · CI watch RSS
- Universidad Autonoma de Nuevo Leon portfolio CI